Sumatriptan succinate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for sumatriptan succinate and what is the scope of patent protection?
Sumatriptan succinate
is the generic ingredient in eight branded drugs marketed by Meridian Medcl, Glaxosmithkline, Antares Pharma Inc, Baxter Hlthcare Corp, Caplin, Dr Reddys, Endo Operations, Eugia Pharma, Fresenius Kabi Usa, Hikma, Norvium Bioscience, Sandoz, Steriscience Speclts, Sun Pharm, Teva Parenteral, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Zydus, Currax, Tonix Meds, Teva Branded Pharm, Aurobindo Pharma, Corepharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, and Watson Labs, and is included in forty-one NDAs. There are thirty-two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Sumatriptan succinate has three hundred and eighty-two patent family members in thirty-one countries.
There are seventeen drug master file entries for sumatriptan succinate. Thirty-five suppliers are listed for this compound. There are four tentative approvals for this compound.
Summary for sumatriptan succinate
International Patents: | 382 |
US Patents: | 32 |
Tradenames: | 8 |
Applicants: | 34 |
NDAs: | 41 |
Drug Master File Entries: | 17 |
Finished Product Suppliers / Packagers: | 35 |
Raw Ingredient (Bulk) Api Vendors: | 116 |
Clinical Trials: | 26 |
Patent Applications: | 3,444 |
Drug Prices: | Drug price trends for sumatriptan succinate |
What excipients (inactive ingredients) are in sumatriptan succinate? | sumatriptan succinate excipients list |
DailyMed Link: | sumatriptan succinate at DailyMed |
Recent Clinical Trials for sumatriptan succinate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Second Affiliated Hospital of Kunming Medical University | Phase 3 |
Second Hospital of Jilin University | Phase 3 |
Beijing Friendship Hospital | Phase 3 |
Generic filers with tentative approvals for SUMATRIPTAN SUCCINATE
Applicant | Application No. | Strength | Dosage Form |
⤷ Sign Up | ⤷ Sign Up | EQ 100MG BASE | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | EQ 50MG BASE | TABLET;ORAL |
⤷ Sign Up | ⤷ Sign Up | EQ 25MG BASE | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for sumatriptan succinate
Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for sumatriptan succinate
US Patents and Regulatory Information for sumatriptan succinate
Expired US Patents for sumatriptan succinate
International Patents for sumatriptan succinate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2748569 | REGULATION ELECTRONIQUE D'UN SYSTEME DE DISTRIBUTION DE MEDICAMENT (ELECTRONIC CONTROL OF DRUG DELIVERY SYSTEM) | ⤷ Sign Up |
New Zealand | 527760 | Nasal devices | ⤷ Sign Up |
United Kingdom | 2391482 | Nasal devices | ⤷ Sign Up |
Portugal | 1180378 | ⤷ Sign Up | |
Japan | 6992215 | ⤷ Sign Up | |
Australia | 2010202927 | ⤷ Sign Up | |
Australia | 2008358027 | Pharmacokinetics of iontophoretic sumatriptan administration | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.